Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFutura Medical Share News (FUM)

Share Price Information for Futura Medical (FUM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 39.00
Bid: 38.50
Ask: 38.75
Change: -0.575 (-1.47%)
Spread: 0.25 (0.649%)
Open: 39.05
High: 39.20
Low: 39.00
Prev. Close: 39.20
FUM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Futura Medical signs license agreement with Thornton & Ross

Tue, 10th Jan 2017 11:05

(ShareCast News) - Futura Medical, an AIM listed innovative healthcare company focused on transdermal technology, has signed a licensing agreement with Thornton & Ross for the commercialisation of TPR100, the company's novel diclofenac gel for pain relief.Thornton & Ross (T&R) is one of the largest consumer health companies in the UK and was acquired by STADA Arzneimittel AG (STADA), the international healthcare group, three years ago.Under the terms of the agreement, T&R will conduct the manufacturing scale-up of TPR100 and hold rights to manufacture, market and distribute the product in the UK for the lifetime of the product's patents, which run to at least 2028 in the UK. Futura will receive an upfront payment and milestone payments up to a certain limit along with royalties on product sales.TPR100, which benefits from the rapid skin permeation rates offered by Futura's proprietary DermaSys delivery system, demonstrated statistically significant results in a 2015 clinical study comparing the product against both placebo and currently marketed products.No further clinical work is expected to be required ahead of regulatory submission by T&R for UK marketing authorisation, anticipated in the second half of 2017.Executive Vice President of Brands at STADA, Dieno George, said: "Thornton & Ross is an ideal partner for Futura, with its expertise in both OTC and Rx marketing and we are very excited to bring TPR100 into our product portfolio. TPR100's topical formulation, and positive trial results achieved to date, mean that it has the potential to be a product that very successfully meets patient needs."Chief executive of Futura, James Barder, said: "We're delighted to sign this licensing agreement with Thornton & Ross for the UK rights to our topical diclofenac gel, TPR100. This agreement is an important milestone for Futura as it marks the first commercial validation of the Company's pain relief portfolio. We look forward to working with Thornton & Ross on the initial manufacturing scale-up of TPR100, followed by its registration and subsequent commercial launch."The share price of Futura was down 0.53% at 56.70p at 1450 GMT on Tuesday.
More News
9 Jan 2013 16:15

Chairman and CEO of Mediterranean Oil & Gas stock up

Both the Chairman and Chief Executive of Mediterranean Oil & Gas (MOG) increased their holdings in the company on Tuesday, one day after it said it was 'pleased' with its production activities in Italy last year, setting the stage for a strong 2013. CEO William Higgs purchased 200,000 shares at 10

Read more
14 Sep 2012 08:46

Future Medical places shares at tiny discount

Futura Medical, best known for its condom products which help maintain a firmer erection during sexual intercourse, is to raise funds through a placing of shares at a tiny discount to the prevailing share price. The company intends to raise £2.08m, gross, through the placing of 3.65m shares at 57p

Read more
28 Aug 2012 11:24

Fall-out between Reckitt Benckiser and Futura over CSD 500

The British firm that says it has created an erection sustaining condom has fallen out with its marketing partner, Reckitt Benckiser, forcing it to go ahead with production on its own. Futura Medical says it was unable to find: "common ground acceptable to both parties in respect of their continued

Read more
14 Feb 2011 14:28

Futura expects lower loss

AIM-quoted erectile dysfunction treatments developer Futura Medical says that its loss fell in 2010. Revenues generated from commercial payments from partners increased from £50,000 to £125,000. The loss fell from £1.51m to £1.32m. There is still £1m in the bank. The CSD500 condom still requir

Read more
29 Jan 2011 14:04

Takeover targets named

Hold on tight, a wave of patent expiries and generic competition could spark another round of consolidation in the pharma and medical devices sector this year. Billions of dollars have been spent on takeovers or pumped into new issues in recent months as confidence in the recovery grows and cash-ri

Read more
18 Jan 2011 16:37

Futura hit by more delays to CSD500

Erectile dysfunction treatments developer Futura Medical says that there will be further delays in the CSD500 condom getting its CE mark but management believes that the regulator's queries can be addressed in a relatively short period of time. The CSD500 condom helps men to maintain a firm erect

Read more
23 Dec 2010 11:37

Small caps round-up: Forte Energy, Futura Medical, Hightex...

Forte Energy has completed a 7,000m drilling program at its A238 uranium anomaly in the north of its leases in Mauritania and a 1,500m diamond drilling program should be completed next month. "These initial results are from the first pass shallow drilling along strike, and confirm the presence of

Read more
8 Sep 2010 16:36

London close: US spurs Footsie recovery

Footsie put its weak start behind it to close with good gains, helped by buoyant trading on Wall Street. US shares recovered from losses yesterday that snapped a recent winning streak. Among the risers here was ARM Holdings. UBS has issued a downbeat assessment of the European semiconductor mark

Read more
8 Sep 2010 14:28

London afternoon: ARM in line for Samsung boost

Footsie emerged from the lunch-time session nursing a small gain, with the majority of the blue-chip index's constituents in positive territory. Chief among them was chip designer ARM Holdings. UBS has issued a downbeat assessment of the European semiconductor market but it has made an exception o

Read more
8 Sep 2010 12:59

Small caps round-up: Ark Therapeutics, Alkane Energy, CPL

Speciality drug developer AGI Therapeutics posted narrower losses in the six months to June 30 and said it was on the look-out for 'external opportunities.' The company, which is developing treatments for gastrointestinal disorders and multiple sclerosis, saw pre-tax losses narrow to $3.1m from $9.

Read more
21 Jul 2010 11:05

CORRECT: =3rd UPDATE: Reckitt Benckiser In GBP2.54B SSL Deal

("=3rd UPDATE: Reckitt Benckiser Agrees GBP2.54B Offer For SSL," at 0911 GMT, misstated Reckitt's total workforce in the last paragraph. The correct version follows:) (Adds detail and analyst's comment.) By Jason Douglas and Michael Carolan Of DOW JONES NEWSWIRES LONDON (Dow Jones)-

Read more
30 Jun 2010 16:00

UK SMALLCAP ROUNDUP: Resaca Exploration Shelves Share Sale

Dow Jones smallcap news is now on Twitter, allowing you to catch up on the news away from your desk. Go to http://twitter.com/DJ_UK_Smallcaps RESACA EXPLOITATION INC. (RSOX.LN), an oil and gas company, said Wednesday it postponed a planned share issue due to market conditions. Resaca planne

Read more
30 Jun 2010 12:30

UK SMALLCAP ROUNDUP: HMV Strategy On Track Amid Record Sales

Dow Jones smallcap news is now on Twitter, allowing you to catch up on the news away from your desk. Go to http://twitter.com/DJ_UK_Smallcaps HMV GROUP PLC (HMV.LN) Wednesday said its strategy of diversifying its business away from CDs and DVDs remains on track, although the CD market didn't de

Read more
30 Jun 2010 08:56

Futura Medical Signs Development Deal With GlaxoSmithKline

LONDON (Dow Jones)--Pharmaceutical company Futura Medical PLC (FUM.LN) Tuesday said it signed a deal with GlaxoSmithKline PLC's (GSK.LN) cosumer healthcare unit to develop a painkiller. GlaxoSmithKline will be responsible for the clinical and regulatory development of Futura's TR100 and Futura w

Read more
12 May 2010 12:36

Small caps round-up: Aurelian, Cineworld, Greggs...

Eastern Europe focused oil and gas explorer and producer Aurelian today reconfirmed "steady" progress against all targets set out in October's strategy document. "We are on track to spud our first two high impact wells in line with our milestones; in June we commence the drilling of the first multi

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.